Lidocaina Cloridrato S.A.L.F.

Lidocaine hydrochloride, the active ingredient in Lidocaina Cloridrato S.A.L.F., is a local anesthetic presented as a sterile injectable solution for intravenous use. It provides rapid, reversible loss of sensation for surgical procedures, regional nerve blocks, and analgesia. GNH USA supplies Lidocaina Cloridrato S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lidocaine hydrochloride is employed in the management of pain and sensation within the surgical and procedural setting. - Surgical procedures: provides localized numbness to facilitate operative interventions. - Regional anesthesia: enables nerve block techniques for limb or trunk anesthesia. - Analgesia: offers pain relief during minor procedures or the postoperative period.

Adverse reactions may occur with intravenous lidocaine administration.

Common Side Effects: - Dizziness or light‑headedness. - Metallic taste in the mouth. - Numbness or tingling at the injection site. - Mild hypotension.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Cardiac arrhythmias, including ventricular tachycardia. - Central nervous system toxicity manifesting as seizures.

When using Lidocaina Cloridrato S.A.L.F., clinicians should consider several safety measures. - Assess cardiac history: avoid rapid IV bolus in patients with conduction disorders. - Monitor blood pressure: watch for hypotension during administration. - Avoid in patients with known lidocaine allergy. - Use caution in hepatic impairment: reduced metabolism may increase exposure. - Store at ambient temperature: keep in original container, protect from moisture and light.

Lidocaine may interact with other medications, requiring careful assessment.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine plasma levels leading to toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance cardiac depressant effects. - Diuretics: may alter plasma protein binding. - Other local anesthetics: additive toxicity risk.